Merck Sharp & Dohme (MSD)

Photo
13.08.2024 • News

MSD to Buy B-Cell Depletion Therapy from Curon

Major US drugmaker MSD is to pay up to $1.3 billion to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from biotechnology company Curon Biopharmaceutical.

Photo
07.08.2024 • News

Daiichi Sankyo and MSD Expand Global Collaboration

Japan's Daiichi Sankyo and US drugmaker MSD have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody drug conjugates to include MSD’s MK-6070, a compound MSD obtained through its recent acquisition of Harpoon Therapeutics.

Photo
19.09.2023 • News

MSD Ireland Opens New Site in Dunboyne, Completes Expansion in Carlow

In Ireland, US drugmaker MSD has opened its new facility in Dunboyne, County Meath, and has expanded its Carlow site. MSD says it has invested more than €1 billion at both sites, creating 670 new jobs and increasing the number of employees in Ireland to 3,100. 100 of the newly created positions remain to be filled.

Photo
15.08.2023 • News

Astex and MSD Expand Drug Discovery Collaboration

UK-based Astex Pharmaceuticals, specialized in the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced an exclusive worldwide research collaboration and license agreement with US drugmaker MSD (in the US, the company trades as Merck & Co).

Photo
08.11.2022 • News

Pharma CEOs Take Action on Climate Change

The CEOs of seven multinational pharmaceutical companies have announced that they are taking joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.

Photo
12.10.2021 • News

Merck & Co Files for Oral Covid Antiviral EUA

US pharma giant Merck & Co has applied to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its oral antiviral drug molnupiravir, developed together with Ridgeback Biotherapeutics. The New Jersey-based pharma and the Florida-headquartered biotech are positioning the pill as a preventative therapy, rather than as a therapeutic, the latter a path other industry heavyweights are taking.

Photo
03.03.2021 • News

US Merck to Make Covid Vaccine for J&J

Another “Big Pharma” company with a stalled candidate of its own is stepping in to help boost national or regional Covid-19 vaccine supply. US president Joe Biden was due to announce on Mar. 2 that Merck & Co will help make the Johnson & Johnson single-shot vaccine that received an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) on Feb. 27.

Photo
09.12.2020 • News

US Merck Divests Moderna Holding

US pharma giant Merck has divested its direct holding in Moderna just as the US biotech is on the cusp of receiving an emergency use authorization (EUA) for its mRNA-based Covid-19. It said it expects to “record a small fourth-quarter gain.”

9 more articles

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.